Dissolvable microarray patches of levodopa and carbidopa for Parkinson’s disease management
[Display omitted] Carbidopa and levodopa remain the established therapeutic standard for managing Parkinson’s disease. Nevertheless, their oral administration is hindered by rapid enzymatic degradation and gastrointestinal issues, limiting their efficacy, and necessitating alternative delivery metho...
Gespeichert in:
Veröffentlicht in: | European journal of pharmaceutics and biopharmaceutics 2024-06, Vol.199, p.114304-114304, Article 114304 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 114304 |
---|---|
container_issue | |
container_start_page | 114304 |
container_title | European journal of pharmaceutics and biopharmaceutics |
container_volume | 199 |
creator | Anjani, Qonita Kurnia Moreno-Castellanos, Natalia Li, Yaocun Sabri, Akmal Hidayat Bin Donnelly, Ryan F. |
description | [Display omitted]
Carbidopa and levodopa remain the established therapeutic standard for managing Parkinson’s disease. Nevertheless, their oral administration is hindered by rapid enzymatic degradation and gastrointestinal issues, limiting their efficacy, and necessitating alternative delivery methods. This work presents a novel strategy employing dissolving microarray patches (MAPs) loaded with carbidopa and levodopa, formulated with Tween® 80 to improve their transdermal delivery. The fabricated MAPs demonstrated an acceptable mechanical strength, resisting pressures equivalent to manual human thumb application (32 N) onto the skin. Additionally, these MAPs exhibited an insertion depth of up to 650 µm into excised neonatal porcine skin. Ex vivo dermatokinetic studies could achieve delivery efficiencies of approximately 53.35 % for levodopa and 40.14 % for carbidopa over 24 h, demonstrating their significant potential in drug delivery. Biocompatibility assessments conducted on human dermal fibroblast cells corroborated acceptable cytocompatibility, confirming the suitability of these MAPs for dermal application. In conclusion, dissolving MAPs incorporating carbidopa and levodopa represent a promising alternative for improving the therapeutic management of Parkinson’s disease. |
doi_str_mv | 10.1016/j.ejpb.2024.114304 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3047941731</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0939641124001309</els_id><sourcerecordid>3047941731</sourcerecordid><originalsourceid>FETCH-LOGICAL-c351t-67b096d543dcd1d88518b3a7863730e08244645f3af2a64ceb5f32083903fed03</originalsourceid><addsrcrecordid>eNp9kLtOxDAQRS0EguXxAxQoJU0WO3YcR6JBvCUkKKBE1sSegJckDnZ2JTp-g9_jS8iyQEk1M9K5V5pDyD6jU0aZPJpNcdZX04xmYsqY4FSskQlTBU-5EGydTGjJy1QKxrbIdowzSqkocrVJtriSkudZNiGPZy5G3yygajBpnQkeQoC3pIfBPGNMfJ00uPDW95BAZxMDoXLfV-1DcgfhxXXRd5_vHzGxLiLEsQY6eMIWu2GXbNTQRNz7mTvk4eL8_vQqvbm9vD49uUkNz9mQyqKipbS54NZYZpXKmao4FEryglOkKhNCirzmUGcghcFq3DOqeEl5jZbyHXK46u2Df51jHHTrosGmgQ79POpRTVEKVnA2otkKHV-NMWCt--BaCG-aUb3Uqmd6qVUvteqV1jF08NM_r1q0f5FfjyNwvAJw_HLhMOhoHHYGrQtoBm29-6__C7ETidc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3047941731</pqid></control><display><type>article</type><title>Dissolvable microarray patches of levodopa and carbidopa for Parkinson’s disease management</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Anjani, Qonita Kurnia ; Moreno-Castellanos, Natalia ; Li, Yaocun ; Sabri, Akmal Hidayat Bin ; Donnelly, Ryan F.</creator><creatorcontrib>Anjani, Qonita Kurnia ; Moreno-Castellanos, Natalia ; Li, Yaocun ; Sabri, Akmal Hidayat Bin ; Donnelly, Ryan F.</creatorcontrib><description>[Display omitted]
Carbidopa and levodopa remain the established therapeutic standard for managing Parkinson’s disease. Nevertheless, their oral administration is hindered by rapid enzymatic degradation and gastrointestinal issues, limiting their efficacy, and necessitating alternative delivery methods. This work presents a novel strategy employing dissolving microarray patches (MAPs) loaded with carbidopa and levodopa, formulated with Tween® 80 to improve their transdermal delivery. The fabricated MAPs demonstrated an acceptable mechanical strength, resisting pressures equivalent to manual human thumb application (32 N) onto the skin. Additionally, these MAPs exhibited an insertion depth of up to 650 µm into excised neonatal porcine skin. Ex vivo dermatokinetic studies could achieve delivery efficiencies of approximately 53.35 % for levodopa and 40.14 % for carbidopa over 24 h, demonstrating their significant potential in drug delivery. Biocompatibility assessments conducted on human dermal fibroblast cells corroborated acceptable cytocompatibility, confirming the suitability of these MAPs for dermal application. In conclusion, dissolving MAPs incorporating carbidopa and levodopa represent a promising alternative for improving the therapeutic management of Parkinson’s disease.</description><identifier>ISSN: 0939-6411</identifier><identifier>EISSN: 1873-3441</identifier><identifier>DOI: 10.1016/j.ejpb.2024.114304</identifier><identifier>PMID: 38663522</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Administration, Cutaneous ; Animals ; Antiparkinson Agents - administration & dosage ; Antiparkinson Agents - pharmacology ; Carbidopa ; Carbidopa - administration & dosage ; Dissolving microarray patches ; Drug Combinations ; Drug Delivery Systems - methods ; Fibroblasts - drug effects ; Fibroblasts - metabolism ; Humans ; Levodopa ; Levodopa - administration & dosage ; Microneedles ; Parkinson Disease - drug therapy ; Parkinson’s disease ; Skin - drug effects ; Skin - metabolism ; Skin Absorption - drug effects ; Swine ; Transdermal Patch</subject><ispartof>European journal of pharmaceutics and biopharmaceutics, 2024-06, Vol.199, p.114304-114304, Article 114304</ispartof><rights>2024</rights><rights>Copyright © 2024. Published by Elsevier B.V.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c351t-67b096d543dcd1d88518b3a7863730e08244645f3af2a64ceb5f32083903fed03</cites><orcidid>0000-0002-3732-4899 ; 0000-0003-2481-3164 ; 0000-0002-0766-4147</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0939641124001309$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38663522$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Anjani, Qonita Kurnia</creatorcontrib><creatorcontrib>Moreno-Castellanos, Natalia</creatorcontrib><creatorcontrib>Li, Yaocun</creatorcontrib><creatorcontrib>Sabri, Akmal Hidayat Bin</creatorcontrib><creatorcontrib>Donnelly, Ryan F.</creatorcontrib><title>Dissolvable microarray patches of levodopa and carbidopa for Parkinson’s disease management</title><title>European journal of pharmaceutics and biopharmaceutics</title><addtitle>Eur J Pharm Biopharm</addtitle><description>[Display omitted]
Carbidopa and levodopa remain the established therapeutic standard for managing Parkinson’s disease. Nevertheless, their oral administration is hindered by rapid enzymatic degradation and gastrointestinal issues, limiting their efficacy, and necessitating alternative delivery methods. This work presents a novel strategy employing dissolving microarray patches (MAPs) loaded with carbidopa and levodopa, formulated with Tween® 80 to improve their transdermal delivery. The fabricated MAPs demonstrated an acceptable mechanical strength, resisting pressures equivalent to manual human thumb application (32 N) onto the skin. Additionally, these MAPs exhibited an insertion depth of up to 650 µm into excised neonatal porcine skin. Ex vivo dermatokinetic studies could achieve delivery efficiencies of approximately 53.35 % for levodopa and 40.14 % for carbidopa over 24 h, demonstrating their significant potential in drug delivery. Biocompatibility assessments conducted on human dermal fibroblast cells corroborated acceptable cytocompatibility, confirming the suitability of these MAPs for dermal application. In conclusion, dissolving MAPs incorporating carbidopa and levodopa represent a promising alternative for improving the therapeutic management of Parkinson’s disease.</description><subject>Administration, Cutaneous</subject><subject>Animals</subject><subject>Antiparkinson Agents - administration & dosage</subject><subject>Antiparkinson Agents - pharmacology</subject><subject>Carbidopa</subject><subject>Carbidopa - administration & dosage</subject><subject>Dissolving microarray patches</subject><subject>Drug Combinations</subject><subject>Drug Delivery Systems - methods</subject><subject>Fibroblasts - drug effects</subject><subject>Fibroblasts - metabolism</subject><subject>Humans</subject><subject>Levodopa</subject><subject>Levodopa - administration & dosage</subject><subject>Microneedles</subject><subject>Parkinson Disease - drug therapy</subject><subject>Parkinson’s disease</subject><subject>Skin - drug effects</subject><subject>Skin - metabolism</subject><subject>Skin Absorption - drug effects</subject><subject>Swine</subject><subject>Transdermal Patch</subject><issn>0939-6411</issn><issn>1873-3441</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kLtOxDAQRS0EguXxAxQoJU0WO3YcR6JBvCUkKKBE1sSegJckDnZ2JTp-g9_jS8iyQEk1M9K5V5pDyD6jU0aZPJpNcdZX04xmYsqY4FSskQlTBU-5EGydTGjJy1QKxrbIdowzSqkocrVJtriSkudZNiGPZy5G3yygajBpnQkeQoC3pIfBPGNMfJ00uPDW95BAZxMDoXLfV-1DcgfhxXXRd5_vHzGxLiLEsQY6eMIWu2GXbNTQRNz7mTvk4eL8_vQqvbm9vD49uUkNz9mQyqKipbS54NZYZpXKmao4FEryglOkKhNCirzmUGcghcFq3DOqeEl5jZbyHXK46u2Df51jHHTrosGmgQ79POpRTVEKVnA2otkKHV-NMWCt--BaCG-aUb3Uqmd6qVUvteqV1jF08NM_r1q0f5FfjyNwvAJw_HLhMOhoHHYGrQtoBm29-6__C7ETidc</recordid><startdate>202406</startdate><enddate>202406</enddate><creator>Anjani, Qonita Kurnia</creator><creator>Moreno-Castellanos, Natalia</creator><creator>Li, Yaocun</creator><creator>Sabri, Akmal Hidayat Bin</creator><creator>Donnelly, Ryan F.</creator><general>Elsevier B.V</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-3732-4899</orcidid><orcidid>https://orcid.org/0000-0003-2481-3164</orcidid><orcidid>https://orcid.org/0000-0002-0766-4147</orcidid></search><sort><creationdate>202406</creationdate><title>Dissolvable microarray patches of levodopa and carbidopa for Parkinson’s disease management</title><author>Anjani, Qonita Kurnia ; Moreno-Castellanos, Natalia ; Li, Yaocun ; Sabri, Akmal Hidayat Bin ; Donnelly, Ryan F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c351t-67b096d543dcd1d88518b3a7863730e08244645f3af2a64ceb5f32083903fed03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Administration, Cutaneous</topic><topic>Animals</topic><topic>Antiparkinson Agents - administration & dosage</topic><topic>Antiparkinson Agents - pharmacology</topic><topic>Carbidopa</topic><topic>Carbidopa - administration & dosage</topic><topic>Dissolving microarray patches</topic><topic>Drug Combinations</topic><topic>Drug Delivery Systems - methods</topic><topic>Fibroblasts - drug effects</topic><topic>Fibroblasts - metabolism</topic><topic>Humans</topic><topic>Levodopa</topic><topic>Levodopa - administration & dosage</topic><topic>Microneedles</topic><topic>Parkinson Disease - drug therapy</topic><topic>Parkinson’s disease</topic><topic>Skin - drug effects</topic><topic>Skin - metabolism</topic><topic>Skin Absorption - drug effects</topic><topic>Swine</topic><topic>Transdermal Patch</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Anjani, Qonita Kurnia</creatorcontrib><creatorcontrib>Moreno-Castellanos, Natalia</creatorcontrib><creatorcontrib>Li, Yaocun</creatorcontrib><creatorcontrib>Sabri, Akmal Hidayat Bin</creatorcontrib><creatorcontrib>Donnelly, Ryan F.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of pharmaceutics and biopharmaceutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Anjani, Qonita Kurnia</au><au>Moreno-Castellanos, Natalia</au><au>Li, Yaocun</au><au>Sabri, Akmal Hidayat Bin</au><au>Donnelly, Ryan F.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dissolvable microarray patches of levodopa and carbidopa for Parkinson’s disease management</atitle><jtitle>European journal of pharmaceutics and biopharmaceutics</jtitle><addtitle>Eur J Pharm Biopharm</addtitle><date>2024-06</date><risdate>2024</risdate><volume>199</volume><spage>114304</spage><epage>114304</epage><pages>114304-114304</pages><artnum>114304</artnum><issn>0939-6411</issn><eissn>1873-3441</eissn><abstract>[Display omitted]
Carbidopa and levodopa remain the established therapeutic standard for managing Parkinson’s disease. Nevertheless, their oral administration is hindered by rapid enzymatic degradation and gastrointestinal issues, limiting their efficacy, and necessitating alternative delivery methods. This work presents a novel strategy employing dissolving microarray patches (MAPs) loaded with carbidopa and levodopa, formulated with Tween® 80 to improve their transdermal delivery. The fabricated MAPs demonstrated an acceptable mechanical strength, resisting pressures equivalent to manual human thumb application (32 N) onto the skin. Additionally, these MAPs exhibited an insertion depth of up to 650 µm into excised neonatal porcine skin. Ex vivo dermatokinetic studies could achieve delivery efficiencies of approximately 53.35 % for levodopa and 40.14 % for carbidopa over 24 h, demonstrating their significant potential in drug delivery. Biocompatibility assessments conducted on human dermal fibroblast cells corroborated acceptable cytocompatibility, confirming the suitability of these MAPs for dermal application. In conclusion, dissolving MAPs incorporating carbidopa and levodopa represent a promising alternative for improving the therapeutic management of Parkinson’s disease.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>38663522</pmid><doi>10.1016/j.ejpb.2024.114304</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-3732-4899</orcidid><orcidid>https://orcid.org/0000-0003-2481-3164</orcidid><orcidid>https://orcid.org/0000-0002-0766-4147</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0939-6411 |
ispartof | European journal of pharmaceutics and biopharmaceutics, 2024-06, Vol.199, p.114304-114304, Article 114304 |
issn | 0939-6411 1873-3441 |
language | eng |
recordid | cdi_proquest_miscellaneous_3047941731 |
source | MEDLINE; Elsevier ScienceDirect Journals |
subjects | Administration, Cutaneous Animals Antiparkinson Agents - administration & dosage Antiparkinson Agents - pharmacology Carbidopa Carbidopa - administration & dosage Dissolving microarray patches Drug Combinations Drug Delivery Systems - methods Fibroblasts - drug effects Fibroblasts - metabolism Humans Levodopa Levodopa - administration & dosage Microneedles Parkinson Disease - drug therapy Parkinson’s disease Skin - drug effects Skin - metabolism Skin Absorption - drug effects Swine Transdermal Patch |
title | Dissolvable microarray patches of levodopa and carbidopa for Parkinson’s disease management |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T00%3A18%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dissolvable%20microarray%20patches%20of%20levodopa%20and%20carbidopa%20for%20Parkinson%E2%80%99s%20disease%20management&rft.jtitle=European%20journal%20of%20pharmaceutics%20and%20biopharmaceutics&rft.au=Anjani,%20Qonita%20Kurnia&rft.date=2024-06&rft.volume=199&rft.spage=114304&rft.epage=114304&rft.pages=114304-114304&rft.artnum=114304&rft.issn=0939-6411&rft.eissn=1873-3441&rft_id=info:doi/10.1016/j.ejpb.2024.114304&rft_dat=%3Cproquest_cross%3E3047941731%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3047941731&rft_id=info:pmid/38663522&rft_els_id=S0939641124001309&rfr_iscdi=true |